Stellar Biotech & iiMedia Research Jointly Launch 2025 China Innovative Drugs Global Expansion Leadership Ranking

Driven by the restructuring of the global pharmaceutical innovation landscape and continuous policy dividends in China, China’s innovative drug sector has evolved from the early stage of out-licensing (“borrowing ships to sail overseas”) to a new phase of deep participation in global value chain distribution.

Industry transaction volume exceeded USD 30 billion in 2023 and is expected to reach USD 100 billion by 2027. In the first 8 months of 2025 alone, total license-out transactions surpassed USD 66 billion, demonstrating strong industrial momentum. Against this critical backdrop, the iiMedia Ranking · 2025 China Innovative Drugs Global Expansion Leadership Ranking was initiated by Stellar Biotech and jointly launched by iiMedia Research, providing an authoritative benchmark and practical empowerment platform for pharmaceutical and medical device enterprises going global.

Practical Implementation Expert with Deep Regional Insights As a global life and health company, Stellar Biotech operates a dual-headquarters global layout and has built a mature distribution network across six core markets in Southeast Asia, Hong Kong, and Macao. Backed by a professional team with over 20 years of international registration experience and extensive practical cases in pharmaceutical and medical device globalization, Stellar Biotech provides end-to-end support for pharmaceutical enterprises, covering regulatory approval, localized distribution, and compliance risk control. Its in-depth cooperation with well-known pharmaceutical companies including 3SBio and CStone Pharmaceuticals has widely recognized its service capabilities for Southeast Asia market entry.

Authoritative Data Institution in the New Economy Sector iiMedia Research has long focused on the new economy industry, serving more than 3,800 government and enterprise clients. Its research results have been cited over 50 million times by global mainstream media, listed company financial reports, and academic journals. Supported by a provincial-level major science and technology project — China Mobile Internet Big Data Mining and Analysis System (CMDAS), iiMedia Research covers omni-channel data resources across 135 countries and regions, drawing on authoritative sources including its proprietary pharmaceutical database, customs import and export monitoring data, and cross-border pharmaceutical cooperation announcements, providing solid data support for industry evaluation.

A key highlight of the Leadership Ranking is its four-in-one value evaluation system: Technical Barriers + Global Progress + Commercialization Potential + Regional Implementation Capability, breaking through the limitations of traditional single-dimensional rankings.

Upgraded based on iiMedia’s mature iiMeval big data evaluation model, the system includes 15 core indicators: On the basis of 12 existing indicators such as FDA/EMA certifications, overseas clinical progress, and global patent layout, three practical indicators are newly added:

Indicator weights are dynamically adjusted according to industry trends and regional market characteristics, emphasizing original innovation, overseas clinical progress, commercialization capabilities, and regional adaptation efficiency, avoiding one-sided judgments based on single data points.

This ranking goes far beyond a simple list of enterprise capabilities. Through the full-chain service model: Selection → Global Release → Resource Matching → On-the-Ground Empowerment, it provides actionable models for pharmaceutical and medical device globalization.

Leveraging iiMedia Research’s industry integration capabilities and Stellar Biotech’s practical service strengths, the platform offers enterprises end-to-end support including overseas patient sentiment analysis, regional policy adaptation advice, and cross-border cold-chain logistics solutions. For emerging biotech companies that have completed Phase I overseas clinical trials, it also provides cross-border financing training, international compliance support, and fast-track market access in Southeast Asia, effectively easing the globalization pressure for biotech enterprises.

Through quantifiable scientific indicators, the ranking establishes clear benchmarks for innovation and regional implementation, guiding enterprises to focus on the R&D of globally competitive FIC/BIC drugs and break away from low-level redundant innovation. This drives industrial resources to concentrate on enterprises with real global innovation and implementation capabilities, improving overall resource allocation efficiency.

Covering core stakeholders including pharmaceutical enterprises, investment institutions, government authorities, and academic institutions, the ranking plays an important role in:

Through a B2B2C linkage model and Stellar Biotech’s localized operational experience in Southeast Asia, the ranking systematically demonstrates the clinical value and regional adaptability of China’s flagship innovative drugs and innovative traditional Chinese medicines, breaking the international stereotype that “China’s innovative drugs are only me-too products”.

In the long run, it will help China gradually gain a stronger voice in international intellectual property and standard-setting in advantageous sectors such as ADC, bispecific antibodies, and innovative TCM, strengthening the influence of China’s innovative drugs in Southeast Asia and countries along the “Belt and Road”.

From “catching up” to “running neck-and-neck” and even “leading” in some fields, China’s innovative drug industry is embarking on a new journey of high-quality globalization. With its scientific evaluation system, profound industry accumulation, extensive resource network, and professional implementation capabilities, the iiMedia Ranking · 2025 China Innovative Drugs Global Expansion Leadership Ranking will continue to guide capital and resources toward truly globally valuable innovative projects, helping China become an important source of global pharmaceutical innovation.